NYSEHealth CareHealth Care TechnologyS&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
DOCS 8-K filings in 2025
Every material Form 8-K Doximity filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Doximity reported fiscal 2026 second-quarter results for the three months ended September 30, 2025, with revenue up 23% year over year and net income rising to $62.1 million from $44.2 million. The company also set fiscal third-quarter guidance and updated its full-year fiscal 2026 revenue and adjusted EBITDA guidance, which the filing does not compare with prior figures.
Revenue of $168.5 million, up 23% from $136.8 million a year earlier
Diluted net income per share of $0.31, versus $0.22; operating cash flow of $93.9 million, up 37%
Fiscal third-quarter (ending December 31, 2025) guidance: revenue of $180 million to $181 million and adjusted EBITDA of $103 million to $104 million
Updated fiscal 2026 (ending March 31, 2026) guidance: revenue of $640 million to $646 million and adjusted EBITDA of $351 million to $357 million
Doximity said its General Counsel, Corporate Secretary, and Chief Compliance Officer, Jennifer Chaloemtiarana, will step down from those roles effective August 29, 2025. John Vaughan will take over all three positions on the same date, and she will stay on in an advisory capacity through November 17, 2025.
Jennifer Chaloemtiarana steps down as General Counsel, Corporate Secretary, and Chief Compliance Officer effective August 29, 2025
John Vaughan assumes all three positions on August 29, 2025
Chaloemtiarana remains employed in an advisory role through November 17, 2025, then receives post-employment payments under her August 10, 2020 offer letter
Doximity reported fiscal first-quarter 2026 results for the quarter ended June 30, 2025, with revenue up 15% year over year and net income rising to $53.3 million from $41.4 million. The company also issued fiscal second-quarter guidance and updated its full-year fiscal 2026 outlook, which shareholders can use to compare against future results.
Revenue of $145.9 million, up 15% from $126.7 million; adjusted EBITDA of $79.8 million, up 21%
Diluted net income per share of $0.27, versus $0.21; operating cash flow of $62.1 million, up 51%
Fiscal 2026 guidance updated to revenue of $628 million to $636 million and adjusted EBITDA of $341 million to $349 million
Doximity said co-founder Dr. Nathan Gross will step down as Chief Strategy Officer effective June 16, 2025, and become an advisor under an Independent Contractor Agreement dated June 13, 2025. The filing says he will receive no cash compensation for advisory services, and his existing equity awards will continue to vest through September 2025.
Dr. Nathan Gross notified the company on June 10, 2025 of his transition; the change takes effect June 16, 2025.
Advisor Agreement is dated June 13, 2025 and runs until terminated under its terms; no cash compensation will be paid.
RSU and option awards granted to Dr. Gross will continue to vest through September 2025.
The company expects to file the Advisor Agreement as an exhibit to its Form 10-Q for the quarter ending June 30, 2025.
Doximity reported fourth-quarter and fiscal 2025 results for the period ended March 31, 2025, with revenue, net income and cash flow all higher than a year earlier. The company also issued revenue and adjusted EBITDA guidance for the fiscal first quarter and full fiscal 2026, which shareholders can compare against these results.
Q4 revenue of $138.3 million, up 17% from $118.1 million; Q4 net income of $62.5 million versus $40.6 million
Fiscal 2025 revenue of $570.4 million, up 20%; net income of $223.2 million versus $147.6 million
Q4 diluted net income per share of $0.31 versus $0.20; Q4 free cash flow of $97.0 million, up 56%
Fiscal 2026 guidance: revenue of $619 million to $631 million and adjusted EBITDA of $333 million to $345 million
Doximity reported fiscal third-quarter 2025 results for the quarter ended December 31, 2024, with revenue of $168.6 million, up 25% year over year, and net income of $75.2 million, up from $48.0 million. The company also issued fourth-quarter guidance of $132.5 million to $133.5 million in revenue and updated its fiscal 2025 revenue guidance to $564.6 million to $565.6 million.
Q3 revenue of $168.6 million versus $135.3 million a year earlier, up 25%
Diluted net income per share of $0.37 versus $0.24; adjusted EBITDA of $102.0 million, up 39%
Q4 guidance: revenue of $132.5 million to $133.5 million; adjusted EBITDA of $62.5 million to $63.5 million
Fiscal 2025 guidance updated to revenue of $564.6 million to $565.6 million and adjusted EBITDA of $306.6 million to $307.6 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Doximity filing is on SEC EDGAR ↗. 8-K briefs of other companies →